Trial Profile
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms Meridian
- Sponsors Chugai Pharmaceutical; Roche
- 28 Apr 2020 Results (n=1427) assessing the prognostic value of the T effector RNA gene signature (Teff) in four studies (BO20289, NO17629, GO25632 and OAM4861G), presented at the 111th Annual Meeting of the American Association for Cancer Research - I.
- 02 Jul 2019 This trial has been Discontinued in UK (End date: 2017-11-21) according to European Clinical Trials Database record
- 24 Apr 2018 This trial has been Discontinued in Belgium (End date: 2017-11-21) according to European Clinical Trials Database record